Deucravacitinib at EULAR 2022 Save
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on:
- Safety of Deucravacitinib https://bit.ly/3NtZQxe
- Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on:
- Safety of Deucravacitinib https://bit.ly/3NtZQxe
- Deucravacitinib in SLE https://bit.ly/3Mh5nG0
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.